Global Next-Generation Biomanufacturing Market Size (2024 – 2030)

Global next-generation biomanufacturing market was valued at USD 22.51 billion and is projected to reach a market size of USD 43.31 billion by the end of 2030. Over the forecast period of 2024-2030, the market is projected to grow at a CAGR of 9.8%. Increasing biologics and biosimilars approvals, growing adoption of automation technologies among biomanufacturing vendors, increasing development and commercialization of digital bioreactors, increasing investment in R&D, and a vast range of advantages such as efficient bioproduction workflow with reduced cost, time, and labor are some factors majorly driving the growth of the next generation biomanufacturing market.

Industry Overview:

Biomanufacturing is the process involving the production of commercially important biomolecules by using biological systems for applications in medicines, industrial applications, and food and beverage processing. Natural sources including blood, animal cells, plant cells, and cultures of microbes, are often utilized to carry out biomanufacturing. Cells utilized in the production process can also be derived by genetic engineering techniques. The next generation of biomanufacturing plants has significantly increased the supply of biologic medicines owing to growing awareness among the people. Increasing commercialization and pipeline therapy product development owing to the growing prevalence of cancer, diabetes, and liver and kidney diseases worldwide are expanding the market growth. The adoption of automation technologies is gaining prominence in the biomanufacturing industry over the years as they provide streamlined control, greater speed, accuracy, and productivity. The growing number of biopharmaceutical companies across the world is anticipated to drive the next generation bio-manufacturing market in the coming years. Many companies are innovating products to enter the next-generation biomanufacturing market, which is likely to drive growth in the forthcoming years.

COVID-19 pandemic impact on Next Generation Biomanufacturing Market

The COVID-19 outbreak accelerated the development of vaccines in biomanufacturing industries. The development of advanced vaccines is likely to positively influence the growth of the biopharmaceutical industry post-pandemic. The bioprocessing of a few companies like GE Healthcare was severely impacted by the COVID-19 outbreak owing to the supply-demand gap. The company reported low revenue in bioprocess in 2020. At the same time, key market players like Danaher Corporation experienced high revenue growth owing to the high demand for bioprocess solutions products. COVID-19 outbreak has encouraged biomanufacturing companies in the United States to prioritize the development of vaccines, which is likely to fuel the market over the forecast market.

MARKET DRIVERS:

Increasing biologics and biosimilars approvals are driving the next generation biomanufacturing market

The number of development programs registered in FDA’s Biosimilar Biological Product Development Program is increasing, with 100 biosimilar development programs registered as of Q4 of Fiscal Year 2021. The rise in development and approvals of biosimilars over the past two years has led to a total of 33 approvals across 13 molecules to date. There has been a growth in the availability and usage of biosimilars which is on track to reduce drug costs by USD 100 billion over the next five years. Following the legislation that allows the FDA to approve biosimilars in the US, biological products similar to the reference product in terms of purity, potency, and safety are gradually entering the market. Such developments are augmenting the next-generation biomanufacturing market.

The growing adoption of automation technologies among biomanufacturing vendors is boosting the next generation biomanufacturing market

Automation technologies are increasingly gaining traction in the biomanufacturing industry over the years owing to their benefits in terms of speed, accuracy, and productivity. The automation systems market is growing rapidly with several companies investing and launching new automation solutions in the market to offer a more streamlined and centralized control. Biopharmaceuticals serve as an important part of the drug portfolio of pharmaceutical companies and thus, need to invest in automation and digitalization of biopharma research and development activities to discover new biopharmaceuticals efficiently and develop the resulting manufacturing processes.

Increasing development and commercialization of digital bioreactors and increasing investment in R&D are augmenting the market

The global next-generation biomanufacturing market is growing rapidly owing to the high investments from both public and private sectors to develop facilities equipped with advanced biomanufacturing instruments. Increased funding from private investors and the government for the development of next-generation biomanufacturing facilities is leading to rapid technological advancement in biomanufacturing products. Biopharmaceutical companies are adopting novel biomanufacturing strategies with an increased focus on balancing innovation in process design, efficiency, performance, speed, and cost. Rising commercialization, the growing biopharmaceutical sector,  and the adoption of advanced technology as well as innovation across the globe are likely to accelerate the growth of the next-generation biomanufacturing market.

Efficient bioproduction workflow with reduced cost, time, and labor are some benefits boosting the next generation biomanufacturing market

Improved upstream and downstream processes, as well as the SUS technologies, enable a wide variety of facility options. These processes need fewer facility resources and can be moved and managed within smaller and less expensive facilities. There are a vast number of advantages associated with single-use products such as cost savings, increased flexibility in multi-product facilities, and reduced risk of product contamination.

MARKET RESTRAINTS:

The lack of skilled professionals in the next generation biomanufacturing market can be a restraining factor

Biopharmaceuticals present technological and operational challenges. Production of these complex molecules in a reliable matter at an industrial scale needs manufacturing capabilities of a previously unknown proficiency. The lack of an experienced talent pool in biologics is a primary challenge in the market expansion.  Additionally, long process durations, costly raw materials, low yields, and the need for highly skilled experts for operations in production facilities can be some of the challenging factors.

Complex production steps and complexity in the process operational can slow down the growth of the Next Generation Biomanufacturing Market

Downstream processing consists of a series of unit operations involving different filtration and chromatography steps. Various factors are often related to limited capacity along with these multiple steps, which pose a challenge to product quality and productivity in downstream processing. In downstream processing, resin chromatography columns, have slow mass transfer rates and are oversized to allow for the higher flow rates to increase productivity. Such an oversizing strategy is often costly and inflexible. To increase productivity and flexibility, and decrease costs, there is a movement toward employing continuous processing, which in turn leads to other downstream processing challenges. Many technologies are addressing these downstream processing challenges but their application for biopharmaceutical production is still limited to large-scale production.

NEXT-GENERATION BIOMANUFACTURING MARKET REPORT COVERAGE:

This research report on the global Next-Generation Biomanufacturing Market has been segmented and sub-segmented based on workflow type, application, end-user, and region.

Next-Generation Biomanufacturing Market – By Workflow Type

• Single-Use Upstream Biomanufaturing Workflow

• Upstream Biomanufacturing Workflow

• Downstream Biomanufaturing Workflow

Based on Workflow Type, the Next-Generation Biomanufacturing Market is bifurcated into Single-Use Upstream Biomanufaturing Workflow, Upstream Biomanufacturing Workflow, and Downstream Biomanufaturing Workflow. The Upstream Biomanufacturing Workflow segment held the dominant position in the global next-generation biomanufacturing market. A large number of high-cost equipment is involved in upstream biomanufacturing compared to downstream biomanufacturing. The Downstream Biomanufacturing Workflow segment is estimated to witness a high growth rate during the forecast period owing to continuous product innovations in the chromatography product lines and filtration systems used in downstream processing.

Next-Generation Biomanufacturing Market – By Application

• Monoclonal Antibodies

• Recombinant protein

• Vaccines

• Hormones

• Others

Based on Application, the Next-Generation Biomanufacturing Market is bifurcated into Monoclonal Antibodies, Recombinant proteins, Vaccines, Hormones, and Others. The Monoclonal Antibodies segment is estimated to dominate the next-generation biomanufacturing market owing to the high rate of product approval. The vaccines segment accounted for the second-largest share in the next generation biomanufacturing market owing to the recent coronavirus outbreak which led to considerable development of vaccines.

Next-Generation Biomanufacturing Market – By End User

• Biopharmaceutical Companies

• Research Institutions

• CMOs/CDMOs

Based on the End User, the Next-Generation Biomanufacturing Market is bifurcated into Biopharmaceutical Companies, Research Institutions, and CMOs/CDMOs. Based on end-user, the Biopharmaceutical Companies segment is anticipated to capture the largest revenue share in the next-generation biomanufacturing market. The rapid digitalization with the adoption of artificial intelligence,  digital twins, and augmented reality in the biopharmaceutical industry are offering immense growth opportunities for biomanufacturing to resolve challenges in producing and supplying biologic medicines. Furthermore, the growing commercialization and adoption of novel biomanufacturing strategies to enhance efficiency and productivity, and reduction in operating costs are positively influencing the growth of the Next-Generation Biomanufacturing market worldwide in the forthcoming years. The increasing investor and government funding are other factors further expanding the next-generation biomanufacturing market.

Next-Generation Biomanufacturing Market - By Region

• North America

• Europe

• Asia-Pacific

• Rest of the World

Geographically, the North American Next-Generation Biomanufacturing Market accounted for the largest revenue share in the global market in 2021. This can be attributed to the well-equipped biomanufacturing facilities with advanced infrastructure, strong investments in the biomanufacturing sector, and the presence of several key industry players in the region. The expanding biopharmaceuticals and biologics industry in the North American region is offering huge growth opportunities for the next generation biomanufacturing market, attracting investors to enter this field. The Next-Generation Biomanufacturing Market in Europe is anticipated to account for the second-largest share during the forecast period.

The Asia Pacific Next-Generation Biomanufacturing Market is anticipated to grow at the fastest CAGR during the forecast period. This is attributed to the rising population in countries like China and India. The emerging nations of Asia-Pacific, such as Japan, South Korea, India, Australia, and Singapore, are widely adopting technologically advanced biomanufacturing equipment.  The growth in new capacity installations to meet the rising product demand in developing nations of Asia-Pacific is further likely to boost the next-generation biomanufacturing market growth.

The Next-Generation Biomanufacturing Market in Latin America, the Middle East, and Africa is anticipated to account for the least share in the global market during the forecast period owing to the lower adoption of advanced technology.

Major Key Players in the Market

1. Applikon Biotechnology BV

2. Thermo Fisher Scientific Inc.

3. bbi-biotech GmbH

4. Danaher Corporation

5. Eppendorf AG

6. Esco Group of Companies

7. Meissner Filtration Products, Inc.

8. Merck KGaA, PBS Biotech, Inc.

9. Pierre Guerin

10. Sartorius AG

11. Shanghai Bailun Biotechnology Co. Ltd

12. Solaris Biotechnology Srl

13. GEA Group Aktiengesellschaft

14. ZETA GmbH

Are some leading companies in the global Next-Generation Biomanufacturing Market. The Next-Generation Biomanufacturing Market has witnessed 115 key developments in biomanufacturing and automation by key companies from acquisitions to partnerships and collaborations, over the past five years.

Notable happenings in the Global Next-Generation Biomanufacturing Market in the recent past:

• Partnership- In August 2021, Sartorius Stedim Biotech, a leading international partner in the biopharmaceutical industry, partnered with McMaster University, located in Hamilton, Ontario, Canada to enhance the manufacturing processes of antibody and virus-based treatments for diseases including COVID-19, and genetic disorders, and cancers.
• Collaboration- In September 2021, Thermo Fisher Scientific's clinical sequencing business and AstraZeneca announced the co-development of next-generation sequencing (NGS)-based companion diagnostics (CDx) to strengthen AstraZeneca's expanding portfolio of targeted therapies. The companies announced to collaborate under a multi-year, global agreement.
• Acquisition- In November 2021, Donaldson Company, Inc., a leading worldwide provider of innovative filtration products and solutions, announced the acquisition of Solaris Biotechnology Srl. Solaris develops and manufactures bioprocessing equipment, such as bioreactors, fermenters, and tangential flow filtration systems for their application in biotechnology, food and beverage, and other life sciences markets.
• Collaboration- In February 2020, Honeywell International Inc. collaborated with Bigfinite, Inc. to aid in process automation and technology control with Bigfinite's AI, data analytics, and machine learning platform to enhance the medical therapies by helping pharma and biotech companies.
• Acquisition- In April 2020, Akron Biotech announced the acquisition of Cambryn facility in Sarasota, Florida, from Cambryn Biologics which is a biomanufacturing plant equipped with state-of-the-art equipment.
• Collaboration- In March 2019, Rockwell Automation and GE Healthcare agreed to combine their automation single-use solution expertise to develop bioprocessing operations for digital bioprocessing.